Table 2. Site optimization—Measured outcomes of recipient diabetic NSG mice.
AUC, area under the curve; n/a, not assessed.
| Site | EM CC or NK |
Dose
(k IEQ) |
Median reversal
time (day) |
Mean
postoperative glucose (mg/dl) |
POD 30 IPGTT
AUC (mg/dl*min) |
POD 54 IPGTT
AUC (mg/dl*min) |
Mean C-peptide
(ng/ml) |
| Fat pad | NK | 2 | 7.5 | 286 ± 98 | 25,936 ± 3,155 | 37,581 ± 766 | 1.28 ± 0.64 |
| 4 | 1.5 | 201 ± 118 | 31,990 | n/a | 1.68 ± 1.21 | ||
| EM CC | 2 | 21 | 435 ± 89 | 36,281 ± 6,995 | 28,435 ± 8,007 | 0.56 ± 0.40 | |
| 4 | 1 | 195 ± 82 | 18,003 ± 5,218 | 5,847 ± 1,993 | 1.14 ± 0.85 | ||
| Intramuscular | EM CC | 4 | Undefined | 360 ± 142 | 29,351 ± 5,870 | 29,431 ± 6,467 | 1.55 ± 0.99 |
| Subcutaneous | 8 | 2.5 | 326 ± 117 | 15,253 ± 6,421 | n/a | 1.57 ± 1.20 |